Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis

NCT07290036 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT07290036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07290036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 1
Overall status
Recruiting
Start date
December 10, 2025
Completion date
September 14, 2028
Enrollment
392 (estimated)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

axial spondyloarthritis, psoriatic arthritis